New ALS drug stabilizes decline with a trend toward improved strength, mobility for some (IMAGE)
Caption
Rickey Malloy (left), who receives tofersen treatment for SOD1-ALS at WashU Medicine, plays a round of golf with his wife, Jenny, and their son, Kash. Long-term use of tofersen, a new drug approved by the FDA for this rare genetic form of ALS, delays symptom progression and death and leads to stabilization or improvement in some, according to a study by WashU Medicine researchers and their collaborators.
Credit
Huy Mach
Usage Restrictions
This image is to be used in accordance with the mission, policies and guidelines of Washington University in St. Louis. Visit https://wustl.edu/about/compliance-policies/media-policies/multimedia- use/ for more information.
License
Original content